高齢者における糖尿病治療薬の使い方

出版社： フジメディカル出版
著者：
発行日： 2017-06-01
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784862701626
電子書籍版： 2017-06-01 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,060 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,036 円(税込)

購入する

商品紹介

新たに掲げられた「高齢者糖尿病の血糖コントロール目標（HbA1c値）」に対して，具体的にどのように対応すべきか。高齢者の糖尿病治療における薬剤処方のポイントは何か。高齢者の特徴を踏まえた適切な血糖コントロール目標値の設定と、そのための糖尿病薬物治療のコツを専門医が簡明に解説。

目次

  • 高齢者における糖尿病治療薬の使い方

    ―目次―

    1．高齢者糖尿病の特徴と注意点：基本知識
    　1）高齢者の糖尿病の特徴
    　2）糖尿病治療におけるフレイルの意義を考える
    　3）サルコペニア
    　4）認知機能
    　5）ポリファーマシー
    　6）高齢者の低血

    2．高齢者糖尿病の新たな管理目標値とその考え方
    　高齢者糖尿病の新たな管理目標値とその考え方

    3．高齢者糖尿病における経口糖尿病薬の使い方
    　1）インスリン分泌促進系
    　　　　SU薬
    　　　　グリニド薬
    　　　　DPP-4阻害薬
    　2）インスリン抵抗性改善系
    　　　　ビグアナイド薬
    　　　　チアゾリジン薬
    　3）糖吸収・排泄調節系
    　　　　α-グルコシダーゼ阻害薬
    　　　　SGLT2阻害薬
    　4）GLP-1受容体作動薬
    　5）高齢者における併用療法
    　　　DPP-4阻害薬 ＋ メトホルミン
    　　　DPP-4阻害薬 ＋ SU薬orグリニド薬
    　　　SGLT2阻害薬を用いた併用
    4．高齢者糖尿病におけるインスリン薬の使い方−課題と対策―
    　1）１型糖尿病
    　2）2型糖尿病

    5．合併症を有する高齢者糖尿病における糖尿病薬治療
    　1）糖尿病性腎症
    　2）認知症

    6．トピックス
    　1）糖尿病とがん
    　2）糖尿病と認知症
    　3）糖尿病と骨折
    　4）心血管イベントに関する糖尿病治療薬の最新のエビデンス
    　5）「高齢者の安全な薬物療法ガイドライン2015」のインパクト

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 高齢者糖尿病の特徴と注意点 : 基本知識

P.17 掲載の参考文献
1) 総務省 : 人口推計 (平成28年10月1日現在) 結果の要約 (http://www.stat.go.jp/data/jinsui/2016np/index.htm)
 
2) 国立社会保障・人口問題研究所の将来人口推計 (http://www.ipss.go.jp/syoushika/tohkei/newest04/point.pdf)
 
3) 「糖尿病」編集委員会 : 糖尿病実態調査の概要 (速報分). 糖尿病 41 : 325-331, 1998
 
4) 厚生労働省健康局総務課生活習慣病対策室 : 平成14年度糖尿病実態調査, 2003
 
5) 厚生労働省健康局総務課生活習慣病対策室 : 平成19年国民健康・栄養調査結果の概要, 2008.12
 
6) 厚生労働省健康局がん対策・健康増進課 : 平成24年国民健康・栄養調査結果の概要, 2013.12
 
7) Cowie CC et al : Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 32 : 287-294, 2009
 
8) Shimokata H et al : Age as independent determinant of glucose tolerance. Diabetes 40 : 44-51, 1991
PubMed
9) Davidson MB : The effect of aging on carbohydrate metabolism : a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly. Metabolism 28 : 688-705, 1979
 
10) 井藤英喜 : 高齢者のエネルギー・糖代謝の特徴. 日本臨牀 74 (増刊号 2) : 529-536, 2016
 
11) 後藤由夫ほか, 日本臨床内科医会調査研究グループ : 糖尿病性神経障害に関する調査研究 第1報わが国の糖尿病の実態と合併症. 日本臨床内科医会会誌 16 : 167-195, 2001
Medical*Online
12) Huang ES et al : Rates of complications and mortality in older patients with diabetes mellitus : the diabetes and aging study. JAMA Intern Med 174 : 251-258, 2014
PubMed
13) Bremer JP et al : Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 32 : 1513-1517, 2009
PubMed
14) Kronmal RA et al : Mortality in pharmacologically treated older adults with diabetes : the Cardiovascular Health Study, 1989-2001. PLoS Med 3 : e400, 2006
PubMed
15) James BD et al : Contribution of Alzheimer disease to mortality in the United States. Neurology 82 : 1045-1050, 2014
PubMed
16) Vijan S et al : Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 174 : 1227-1234, 2014
PubMed
P.21 掲載の参考文献
1) Fried LP et al : Frailty in older adults : evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56 : M146-156, 2001
PubMed
2) Satake S et al : Validity of the Kihon Checklist for assessing frailty status. Geriatr Gerontol Int 16 : 709-715, 2016
PubMed
3) Yamada M, Arai H : Predictive Value of Frailty Scores for Healthy Life Expectancy in Community-Dwelling Older Japanese Adults. J Am Med Dir Assoc 16 : 1002. e7-11, 2015
 
P.26 掲載の参考文献
1) 葛谷雅文 : 老年医学におけるSarcopenia & Frailtyの重要性. 日老医誌 46 : 279-285, 2009
 
2) Cruz-Jentoft AJ et al : Sarcopenia : European consensus on definition and diagnosis : Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39 : 412-423, 2010
 
3) Chen LK et al : Sarcopenia in Asia : consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15 : 95-101, 2014
 
4) 葛谷雅文 : サルコペニアの診断・病態・治療. 日老医誌 52 : 343-349, 2015
 
5) Layman DK et al : Defining meal requirements for protein to optimize metabolic roles of amino acids. Am J Clin Nutr, 2015 [Epub ahead of print]
 
6) Park SW et al; Health, Aging, and Body Composition Study : Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 32 : 1993-1997, 2009
PubMed
7) Park SW et al : Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes : the health, aging, and body composition study. Diabetes Care 30 : 1507-1512, 2007
PubMed
8) Volpato S et al : Role of muscle mass and muscle quality in the association between diabetes and gait speed. Diabetes Care 35 : 1672-1679, 2012
PubMed
9) Lee CG et al : Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. J Am Geriatr Soc 59 : 1217-1224, 2011
PubMed
10) Barzilay JI et al : Insulin resistance is associated with decreased quadriceps muscle strength in nondiabetic adults aged > or=70 years. Diabetes Care 32 : 736-738, 2009
PubMed
11) Larsen BA et al : Association of Muscle Mass, Area, and Strength With Incident Diabetes in Older Adults : The Health ABC Study. J Clin Endocrinol Metab 101 : 1847-1855, 2016
PubMed
12) Li JJ et al : Muscle grip strength predicts incident type 2 diabetes : Population-based cohort study. Metabolism 65 : 883-892, 2016
PubMed
13) Wang X et al : Insulin resistance accelerates muscle protein degradation : Activation of the ubiquitinproteasome pathway by defects in muscle cell signaling. Endocrinology 147 : 4160-4168, 2006
PubMed
14) Lee CG et al : Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 34 : 2381-2386, 2011
PubMed
15) Rizzo MR et al : Sarcopenia in Elderly Diabetic Patients : Role of Dipeptidyl Peptidase 4 Inhibitors. J Am Med Dir Assoc 17 : 896-901, 2016
PubMed
16) Aghili R et al : Body composition in adults with newly diagnosed type 2 diabetes : effects of metformin. J Diabetes Metab Disord 13 : 88, 2014
PubMed
P.32 掲載の参考文献
1) 厚生労働省HP認知症施策推進総合戦略 (新オレンジプラン) ～認知症高齢者等にやさしい地域づくりに向けて～の概要 (http://www.mhlw.go.jp/file/04-Houdouhappyou-12304500-Roukenkyoku-Ninchishougyakutaiboushitaisakusuishinshitsu/01_1.pdf)
 
2) Cheng G et al : Diabetes as a risk factor for dementia and mild cognitive impairment : a meta-analysis of longitudinal studies. Intern Med J 42 : 484-491, 2012
PubMed
3) Strachan MW et al : Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20 : 438-445, 1997
 
4) 櫻井孝 : 高齢者糖尿病の管理 (血糖管理を中心に). 糖尿病 57 : 696-698, 2014
 
5) Ma F et al : Conversion of mild cognitive impairment to dementia among subjects with diabetes : a population-based study of incidence and risk factors with five years of follow-up. J Alzheimers Dis 43 : 1441-1449, 2015
 
6) Yaffe K et al : Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 10 : 293-295, 2006
PubMed
7) Crane PK et al : Glucose levels and risk of dementia. N Engl J Med 369 : 540-548, 2013
PubMed
8) Ohara T e t al : Glucose tolerance s tatus and risk of dementia in the community : the Hisayama study. Neurology 77 : 1126-1134, 2011
 
9) Luchsinger JA et al : Improved diabetes control in the elderly delays global cognitive decline. J Nutr Health Aging 15 : 445-449, 2011
PubMed
10) Bramlage P et al : Oral antidiabetic treatment in type-2 diabetes in the elderly : balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol 11 : 122, 2012
PubMed
11) Davis KL et al : Association between different hemoglobin A1c levels and clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus. J Am Med Dir Assoc 15 : 757-762, 2014
PubMed
12) Whitmer RA et al : Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301 : 1565-1572, 2009
PubMed
13) Koekkoek PS et al : Cognitive function in patients with diabetes mellitus : guidance for daily care. Lancet Neurol 14 : 329-340, 2015
PubMed
14) Araki A et al : Non-high-density lipoprotein cholesterol : an important predictor of stroke and diabetesrelated mortality in Japanese elderly diabetic patients. Geriatr Gerontol Int 12 (Suppl 1) : 18-28, 2012
 
15) 日本糖尿病学会HP (http://www.jds.or.jp/modules/important/index.php?page=article&storyid=66)
 
16) 日本老年医学会HP (https://www.jpn-geriat-soc.or.jp/tool/tool_01.html)
 
17) Perneczky R et al : Mapping scores onto stages : mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry 14 : 139-144, 2006
PubMed
18) Larson EB et al : New insights into the dementia epidemic. N Engl J Med 369 : 2275-2277, 2013
PubMed
P.37 掲載の参考文献
1) Stewart D et al : Guidance to manage inappropriate polypharmacy in older people : systematic review and future developments. Expert Opin Drug Saf 16 : 203-213, 2017
PubMed
2) Mortazavi SS et al : Defining polypharmacy in the elderly : a systematic review protocol. BMJ Open 6 : e010989, 2016
PubMed
3) Poudel A et al : Adverse Outcomes in Relation to Polypharmacy in Robust and Frail Older Hospital Patients. J Am Med Dir Assoc 17 : 767.e9-767.e13, 2016
 
4) 日本老年医学会編 : 高齢者の安全な薬物療法ガイドライン2015, メジカルビュー社, 東京, 2015, pp12-13
 
5) Klotz U : Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41 : 67-76, 2009
PubMed
6) Benedetti MS et al : Drug metabolism in the paediatric population and in the elderly. Drug Discov Today 12 : 599-610, 2007
PubMed
7) Reeve E et al : Alterations in drug disposition in older adults. Expert Onin Drug Metab Toxicol 11 : 491-508, 2015
 
8) Kojima T et al : High risk of adverse drug reactions in elderly patients taking six or more drugs : analysis of inpatient database. Geriatr Gerontol Int 12 : 761-762, 2012
PubMed
9) Claxton AJ et al : A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 : 1296-1310, 2001
PubMed
10) American Geriatric Society 2012 Beers Criteria Update Expert Panel : American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60 : 616-631, 2012
 
11) O'Mahony D et al : STOPP/START criteria for potentially inappropriate prescribing in older people : version 2. Age Ageing 44 : 213-218, 2015
PubMed
12) Kuhn-Thiel AM et al : Consensus validation of the FORTA (Fit fOR The Aged) List : a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging 31 : 131-140, 2014
 
P.44 掲載の参考文献
1) Seaquist ER et al : Hypoglycemia and diabetes : a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36 : 1384-1395, 2013
PubMed
2) Bremer JP et al : Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 32 : 1513-1517, 2009
PubMed
3) Warren RE, Frier BM : Hypoglycaemia and cognitive function. Diabetes Obes Metab 7 : 493-503, 2005
PubMed
4) Abdelhafiz AH et al : Hypoglycaemic symptoms and hypoglycaemia threshold in older people with diabetes--a patient perspective. J Nutr Health Aging 17 : 899-902, 2013
PubMed
5) Mattishent K, Loke YK : Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents : a systematic review and meta-analysis. Diabetes Obes Metab 18 : 135-141, 2016
PubMed
6) Abdelhafiz AH et al : Hypoglycemia in older people - a less well recognized risk factor for frailty. Aging Dis 6 : 156-167, 2015
PubMed
7) Schopman JE et al : The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas : a systematic review and meta-analysis. Diabetes Metab Res Rev 30 : 11-22, 2014
PubMed
8) Bramlage P et al : Oral antidiabetic treatment in type-2 diabetes in the elderly : balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol 11 : 122, 2012
PubMed
9) Feil DG et al : Risk of hypoglycemia in older veterans with dementia and cognitive impairment : implications for practice and policy. J Am Geriatr Soc 59 : 2263-2272, 2011
 
10) Katon WJ et al : Association of depression with increased risk of severe hypoglycemic episodes in patients with diabetes. Ann Fam Med 11 : 245-250, 2013
PubMed
11) Abbatecola AM et al : Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia : results from the DIMORA study. J Am Med Dir Assoc 16 : 349.e7-12, 2015
 
12) Rajendran R et al : Temporal patterns of hypoglycaemia and burden of sulfonylurea-related hypoglycaemia in UK hospitals : a retrospective multicentre audit of hospitalised patients with diabetes. BMJ Open 4 (7) : e005165, 2014
PubMed

2 高齢者糖尿病の新たな管理目標値とその考え方

P.51 掲載の参考文献
1) Haneda M, Morikawa A : Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant 24 : 338-341, 2009
PubMed
2) Morikawa A et al : Has the safety of diabetes therapy improved? Lessons from an analysis of diabetic medication-induced severe hypoglycemic cases in an emergency department from 2005 to 2013. Diabetol Int 7 : 274-280, 2016
 
3) Whitmer RA et al : Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301 : 1565-1572, 2009
PubMed
4) Mattishent K, Loke YK : Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents : a systematic review and meta-analysis. Diabetes Obes Metab 18 : 135-141, 2016
PubMed
5) 大庭建三 : 高齢者糖尿病管理のあり方. 日老医誌 49 : 561-568, 2012
 
6) Kirkman MS et al : Diabetes in older adults. Diabetes Care 35 : 2650-2664, 2012
PubMed
7) International Diabetes Federation. Managing older people with type 2 diabetes. Global Guideline. International Diabetes Federation, 2013
 
8) Chow LS et al : Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD. Diabetologia 58 : 1160-1166, 2015
PubMed

3 高齢者糖尿病における経口糖尿病薬の使い方

P.60 掲載の参考文献
1) UK Prospective Diabetes Study (UKPDS) Group : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 : 837-853, 1998
 
2) Ohkubo Y et al : Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 28 : 103-117, 1995
PubMed
3) Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC et al : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 : 2545-2559, 2008
 
4) ADVANCE Collaborative Group, Patel A et al : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 : 2560-2572, 2008
 
5) Duckworth W et al : Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 : 129-139, 2009
PubMed
6) 岩倉敏夫ほか : 糖尿病治療薬による重症低血糖を発症した2型糖尿病患者135人の解析. 糖尿病 55 : 857-865, 2012
 
7) 池口絵里ほか : 薬物治療中に低血糖をきたし緊急入院となった2型糖尿病患者についての検討. 糖尿病 57 : 235-241, 2014
 
8) インクレチンの適正使用に関する委員会. インクレチンとSU薬の適正使用について (2010) (日本糖尿病学会のホームページ, http:/www.jds.or.jp)
 
9) Nagashima K et al : Sulfonylurea and non-sulfonylurea hypoglycemic agents : pharmachological properties and tissue selectivity. Diabetes Res Clin Pract 66 (Suppl 1) : S75-S78, 2004
 
10) Nathan DM et al : Medical management of hyperglycemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy : a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32 : 193-203, 2009
 
11) Matyka K et al : Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 20 : 135-141, 1997
PubMed
12) Zammitt NN, Frier BM : Hypoglycemia in type 2 diabetes : pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28 : 2948-2961, 2005
PubMed
13) Whitmer RA et al : Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301 : 1565-1572, 2009
PubMed
P.67 掲載の参考文献
1) Chiba Y et al : Risk factors associated with falls in elderly patients with type 2 diabetes. J Diabetes Complications 29 : 898-902, 2015
PubMed
2) Zoungas S et al : Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363 : 1410-1418, 2010
PubMed
3) Bremer JP et al : Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 32 : 1513-1517, 2009
PubMed
4) 日本糖尿病学会編著 : 糖尿病治療ガイド2016-2017, 文光堂, 東京, 2016
 
5) Miwa S et al : Efficacy and safety of once daily gliclazide (20mg/day) compared with nateglinide. Endocr J 51 : 393-398, 2004
 
6) Esposito K et al : Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110 : 214-219, 2004
PubMed
7) Nattrass M, Lauritzen T : Review of prandial glucose regulation with repaglinide : a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? Int J Obes Relat Metab Disord 24 (Suppl 3) : S21-S31, 2000
 
8) Rosenstock J et al : Repaglinide versus nateglinide monotherapy : a randomized, multicenter study. Diabetes Care 27 : 1265-1270, 2004
PubMed
9) Kawamori R et al : Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 3 : 302-308, 2012
PubMed
10) Kudo-Fujimaki K et al : Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide. J Diabetes Investig 5 : 400-409, 2014
PubMed
11) Katsuno T et al : Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus. J Diabetes Investig 2 : 204-209, 2011
PubMed
12) Lee P et al : Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus : results from a pooled analysis. J Am Geriatr Soc 60 : 51-59, 2012
PubMed
13) Sorli C et al : Eldely patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine : a meta-analysis of phase III a trials. Drugs Aging 30 : 1009-1018, 2013
 
14) Yoshihara T et al : Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Endocr J 53 : 67-72, 2006
PubMed
15) Kumashiro N et al : Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Endocr J 54 : 163-166, 2007
PubMed
16) 種山岳彦ほか : 日本人2型糖尿病患者に対するミチグリニドカルシウム水和物のインスリン製剤との併用療法における有効性および安全性の検討-プラセボを対照とした無作為化二重盲検法による製造販売後臨床試験-. 薬理と治療 44 : 1165-1177, 2016
Medical*Online
P.71 掲載の参考文献
1) Arnalich F et al : Gut regulatory peptides and pancreatic beta-cell response to nutritional stimuli in the elderly. J Med 21 : 323-330, 1990
PubMed
2) Trahair LG et al : Comparative effects of variations in duodenal glucose load on glycemic, insulinemic, and incretin responses in healthy young and older subjects. J Clin Endocrinol Metab 97 : 844-851, 2012
 
3) Nathanson D et al : Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease. Diabetologia 53 : 277-280, 2010
 
4) Meneilly GS et al : Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24 : 1951-1956, 2001
PubMed
5) Aroda VR et al : Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors : meta-analysis and systematic review. Clin Ther 34 : 1247-1258, 2012
PubMed
6) Karagiannis T et al : Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting : systematic review and meta-analysis. BMJ 344 : e1369, 2012
PubMed
7) Yamane S et al : GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated β-cell damage in Akita mice. J Diabetes Investig 2 : 104-110, 2011
 
8) Aaboe K et al : GLP-1 : physiological effects and potential therapeutic applications. Diabetes Obes Metab 10 : 994-1003, 2008
PubMed
9) Tsukiyama K et al : Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol 20 : 1644-1651, 2006
PubMed
10) Monami M et al : Dipeptidyl peptidase-4 inhibitors and bone fractures : a meta-analysis of randomized clinical trials. Diabetes Care 34 : 2474-2476, 2011
PubMed
11) Aschner P et al : Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 : 2632-2637, 2006
PubMed
12) Pratley RE et al : Alogliptin use in elderly people : a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 57 : 2011-2019, 2009
PubMed
13) Doucet J et al : Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 27 : 863-869, 2011
PubMed
14) Pratley RE et al : Management of type 2 diabetes in treatment-naive elderly patients : benefits and risks of vildagliptin monotherapy. Diabetes Care 30 : 3017-3022, 2007
PubMed
15) Schweizer A et al : Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population > 75 years : a pooled analysis from a database of clinical trials. Diabetes Obes Metab 13 : 55-64, 2011
 
16) Barnett AH et al : Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments : a randomised, double-blind, placebo-controlled trial. Lancet 382 : 1413-1423, 2013
PubMed
17) 日本糖尿病学会ホームページ (http://www.jds.or.jp/)
 
P.76 掲載の参考文献
1) Hamada S, Gulliford MC : Antidiabetic and cardiovascular drug utilisation in patients diagnosed with type 2 diabetes mellitus over the age of 80 years : a population-based cohort study. Age Ageing 44 : 566-573, 2015
 
2) Viollet B et al : Cellular and molecular mechanisms of metformin : an overview. Clin Sci 122 : 253-270, 2012
PubMed
3) Duca FA et al : Metformin activates a duodenal Ampk?dependent pathway to lower hepatic glucose production in rats. Nat Med 21 : 506-511, 2015
PubMed
4) Miller RA et al : Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494 : 256-260, 2013
PubMed
5) Sarabia V et al : Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J Clin Invest 90 : 1386-1395, 1992
PubMed
6) Migoya EM et al : Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 88 : 801-808, 2010
 
7) Mulherin AJ et al : Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 152 : 4610-4619, 2011
PubMed
8) 加来浩平ほか : 2型糖尿病治療におけるメトホルミンの使用実態に関する観察研究 (MORE study). 糖尿病 49 : 325-331, 2006
 
9) Lee CG et al : Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 34 : 2381-2386, 2011
PubMed
10) Aroda VR et al : Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 101 : 1754-1761, 2016
 
11) Klachko D, Whaley-Connell A : Use of Metformin in Patients with Kidney and Cardiovascular Diseases. Cardiorenal Med 1 : 87-95, 2011
PubMed
P.81 掲載の参考文献
1) Yki-Jarvinen H : Thiazolidinediones. N Engl J Med 351 : 1106-1118, 2004
PubMed
2) Kubota N et al : Pioglitazone ameliorates insulin resistance and diabetes by both adiponectine-dependent and -independent pathways. J Biol Chem 281 : 8748-8755, 2006
PubMed
3) Kadowaki T et al : Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116 : 1784-1792, 2006
PubMed
4) Spanheimer R et al : Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from PROactive experience (PROactive 14). Am J Cardiol 104 : 234-239, 2009
PubMed
5) Dormandy JA et al : Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 366 : 1279-1289, 2005
PubMed
6) Yoshii H et al : Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke : the PROFIT-J study. J Atheroscler Thromb 21 : 563-573, 2014
 
7) Modan M et al : Hyperinsulinemia. A link between hypertension obesity and glucose in tolerance. J Clin Invest 75 : 809-817, 1985
PubMed
8) Nishimoto S et al : Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance. Sci Adv 2 : e1501332, 2016
PubMed
9) Guan Y et al : Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaCmediated renal salt absorption. Nat Med 11 : 861-866, 2005
 
10) Loke YK et al : Long-term use of thiazolidinediones and fractures in type 2 diabetes : a meta-analysis. CMAJ 180 : 32-39, 2009
PubMed
11) Zhu ZN et al Risk of fracture with thiazolidinedions : an updated meta-analysis of randomized clinical trials. Bone 68 : 115-123, 2014
 
12) Caisse nationale de l'assurance maladie, Paris, France. Risk of bladder cancer in people with diabetes treated with pioglitazone in France : a group study on SNIIRAM and PMSI data. (http://www.mhlw.go.jp/stf/shingi/2r9852000001hbq8-att/2r9852000001hd4o.pdf)
 
13) Lewis JD et al : Risk of bladder cancer among diabetic patients treated with pioglitazone : interim report of a longitudinal cohort study. Diabetes Care 34 : 916-922, 2011
PubMed
14) Lewis JD et al : Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA 314 : 265-277, 2015
PubMed
P.85 掲載の参考文献
1) 大倉毅ほか : α-グルコシダーゼ阻害薬. 日本臨牀 70 (増刊号3) : 614-619, 2012
Medical*Online
2) 弘世貴久ほか : α-グルコシダーゼ阻害薬 薬理作用と適応. 糖尿病 第2版, 日本医事新報社, 東京, 2007, p9
 
3) 中西理沙 : α-グルコシダーゼ阻害薬. 月刊糖尿病 7 (2) : 6-10, 2015
 
4) Suzuki Y et al : Are the e ffects of alpha-glucosidase inhibitors on c ardiovascular e vents related to elevated levels of hydrogen gas in the gastrointestinal tract? FEBS Lett 583 : 2157-2159, 2009
 
5) Chiasson JL et al : Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial. JAMA 290 : 486-494, 2003
PubMed
6) Kawamori R et al : Voglibose for prevention of type 2 diabetes mellitus : a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373 : 1607-1614, 2009
PubMed
7) Narita T et al : Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 26 : 187-188, 2009
PubMed
8) Lee A et al : The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4 : 329-335, 2002
PubMed
9) Koyama M et al : Inhibition of progressive reduction of islet beta-cell mass in spontaneously diabetic Goto-Kakizaki rats by alpha-glucosidase inhibitor. Metabolism 49 : 347-352, 2000
PubMed
10) Action to Control Cardiovascular Risk in Diabetes Study Group : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 : 2545-2559, 2008
 
P.90 掲載の参考文献
1) 松橋有紀ほか : イプラグリフロジン投与による血糖コントロールと体組成の変化. PROGRESS IN MEDICINE 34 : 1867-1871, 2014
Medical*Online
2) Obata A et al : Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. Endocrinology 157 : 1029-1042, 2016
PubMed
3) Weber MA et al : Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy : a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4 : 211-220, 2016
PubMed
4) Zinman B et al : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
5) Cherney DZ et al : Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 : 587-597, 2014
PubMed
6) Heerspink HJ et al : Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. J Am Soc Nephrol 28 : 368-375, 2017
PubMed
7) Wanner C et al : Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 375 : 323-334, 2016
PubMed
8) FDA Drug Safety Communication : FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood
 
9) Canagliflozin (Invokana, Invokamet) : Drug Safety Communication - Clinical Trial Results Find Increased Risk of Leg and Foot Amputations
 
10) EMA reviews diabetes medicine canagliflozin
PubMed
11) Yokote K et al : Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER) : final results of a post-marketing surveillance study. Expert Opin Pharmacother 17 : 1995-2003, 2016
PubMed
12) 高木秀一ほか : イプラグリフロジン (SGLT2阻害薬) の臨床的効果とBIA 法による体成分変化の検討. PROGRESS IN MEDICINE 34 : 2229-2235, 2014
Medical*Online
13) Sano M et al : Increased grip strength with sodium-glucose cotransporter 2. J Diabetes 8 : 736-737, 2016
PubMed
14) 中村二郎ほか : -糖尿病の死因に関する委員会報告-アンケート調査による日本人糖尿病の死因- 2001～2010年の10年間, 45,708名での検討-. 糖尿病 59 : 667-684, 2016
 
15) 春日雅人ほか : 糖尿病と癌に関する委員会報告. 糖尿病 56 : 374-390, 2013
 
P.97 掲載の参考文献
1) Yabe D, Seino Y : Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes. Expert Rev Endocrinol Metab 9 : 659-670, 2014
PubMed
2) Meier JJ : GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 : 728-742, 2012
 
3) Seino Y, Yabe D : Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 : Incretin actions beyond the pancreas. J Diabetes Investig 4 : 108-130, 2013
PubMed
4) インクレチン (GLP-1受容体作動薬とDPP-4阻害薬) の適正使用に関する委員会 : インクレチン (GLP-1受容体作動薬とDPP-4阻害薬) の適正使用に関するRecommendation. 2011年9月29日改訂版
 
5) Usui R et al : Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes : A caution against inappropriate use in patients with reduced β-cell function. J Diabetes Investig 4 : 585-594, 2013
 
6) Usui R et al : Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylureacombination therapy in Japanese type 2 diabetes : Association of remaining β-cell function and achievement of HbA1c target one year after initiation. J Diabetes Complications 29 : 1203-1210, 2015
 
7) Eng C et al : Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes : a systematic review and meta-analysis. Lancet 384 : 2228-2234, 2014
PubMed
8) Yale JF et al : Adjunctive Lixisenatide Treatment Improves Glycemic Control in Patients with T2DM Irrespective of beta-Cell Function. Can J Diabetes 38 : S50-51, 2014
 
9) Meier JJ : GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 : 728-742, 2012
 
10) Yabe D et al : Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management : assessment of composite end-points. Curr Med Res Opin 31 : 1267-1270, 2015
PubMed
P.101 掲載の参考文献
1) 日本糖尿病学会編著 : 糖尿病治療ガイド2016-2017, 文光堂, 東京, 2016
 
2) 荒木厚 : 高齢者糖尿病の治療ガイドラインの考え方. Geriatric Medicine 53 : 423-429, 2015
Medical*Online
3) Inzucchi SE et al : Management of hyperglycemia in type 2 diabetes : a patient-centered approach : position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35 : 1364-1379, 2012
 
4) Ito H et al : Efficacy and safety of metformin for treatment of type 2 diabetes in elderly Japanese patients. Geriatr Gerontol Int 11 : 55-62, 2011
PubMed
5) Iozzo P et al : Independent influence of age on basal insulin secreaion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab 84 : 863-868, 1999
 
6) Del Prato S et al : Durability of t he e fficacy and s afety of alogliptin c ompared with glipizide in t ype 2 diabetes mellitus : a 2-year study. Diabetes Obes Metab 16 : 1239-1246, 2014
 
7) Migoya EM et al : Dipeptidyl peptitase-4 inhibitors administered in combination with metformin result in an additive increse in the plasma concentration of active GLP-1. Clin Pharmacol Ther 88 : 801-808, 2010
 
8) 日本老年学会, 日本医療研究開発機構研究費・高齢者の薬物治療の安全性に関する研究研究班編 : 高齢者の安全な薬物療法ガイドライン2015, メジカルビュー社, 東京, 2015
 
P.105 掲載の参考文献
1) Inagaki N et al : Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes : a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol 3 : 191-197, 2015
PubMed
2) Tentolouris N et al : A review of nateglinide in the management of patients with type 2 diabetes. Vasc Health Risk Manag 3 : 797-807, 2007
PubMed
3) Malaisse WJ : Mitiglinide : a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother 9 : 2691-2698, 2008
PubMed
4) Scott LJ : Repaglinide : a review of its use in type 2 diabetes mellitus. Drugs 72 : 249-272, 2012
PubMed
5) 「インクレチン (GLP-1受容体作動薬とDPP-4阻害薬) の適正使用に関する委員会」から. 日本糖尿病学会 (http://www.jds.or.jp/)
 
6) Mukai E et al : Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes 60 : 218-226, 2011
 
7) 加来浩平ほか : α-グルコシダーゼ阻害薬. 糖尿病治療のニューパラダイム第2巻, 薬物療法の実践～血糖降下薬を中心に～ , 医薬ジャーナル社, 大阪, 2014, pp37-44
 
8) Hanefeld M et al : Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 23 : 202-207, 2000
PubMed
9) Huang ES et al : Glycemic control, complications, and death in older diabetic patients : the diabetes and aging study. Diabetes Care 34 : 1329-1336, 2011
 
10) Araki A et al; Japanese Elderly Intervention Trial Research Group : Non-high-density lipoprotein cholesterol : an important predictor of stroke and diabetes-related mortality in Japanese elderly diabetic patients. Geriatr Gerontol Int 12 (Suppl 1) : 18-28, 2012
 
P.113 掲載の参考文献
1) 井藤英喜 : 超少子高齢社会と糖尿病診療. 月刊糖尿病 6 : 8-14, 2014
 
2) 高齢者糖尿病の治療向上のための日本糖尿病学会と日本老年医学会の合同委員会 : 高齢者糖尿病の血糖コントロール目標について, 日本糖尿病学会ホームページ (http://www.jds.or.jp/modules/important/index.php?page=article&storyid=66)
 
3) 糖尿病治療ガイド2014-2015, 文光堂, 東京, 2014, p29
 
4) SGLT2阻害薬の適正使用に関する委員会 : SGLT2阻害薬の適正使用に関する Recommendation, 策定 : 2014年6月13日, 改訂 (第1回) : 2014年8月29日, 改訂 (第2回) : 2016年5月12日. (http://www.fa.kyorin.co.jp/jds/uploads/recommendation_SGLT2.pdf)
 
5) Yokote K et al : Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER) : final results of a post-marketing surveillance study. Expert Opin Pharmacother 17 : 1995-2003, 2016
PubMed
6) 吉田茂ほか : 高齢者2型糖尿病に対するダパグリフロジンの安全性および有効性の検討-ダパグリフロジン特定使用成績調査結果の中間報告-. 薬理と治療 44 : 347-370, 2016
Medical*Online
7) 山倉朋子ほか : 高齢2型糖尿病患者におけるカナグリフロジンの特定使用成績調査 (中間報告) -高齢者の特性をふまえて-. 薬理と治療 44 : 1281-1294, 2016
Medical*Online
8) 清野裕, 黒瀬健 : SGLT2阻害薬の臨床データをみる-臨床治験データより-. SGLT2阻害薬のすべて, 先端医学社, 東京, 2014, pp42-52
 
9) Zinman B et al ; EMPA-REG OUTCOME Investigators : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
10) Fitchett D et al; EMPA-REG OUTCOMER trial investigators : Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk : results of the EMPA-REG OUTCOMER trial. Eur Heart J 37 : 1526-1534, 2016
 
11) Wanner C et al; EMPA-REG OUTCOME Investigators : Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 375 : 323-334, 2016
PubMed
12) 竹田孔明, 谷澤幸生 : 作用の違いから併用の可能性と有用性を探る. SGLT2阻害薬のすべて, 先端医学社, 東京, 2014, pp118-125
 
13) Watts NB et al : Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 101 : 157-166, 2016
PubMed
14) 森豊 : SGLT2阻害薬の位置づけと具体的な使われ方. 医療スタッフのための糖尿病情報BOX&Net., No.42, 2014
 

4 高齢者糖尿病におけるインスリン薬の使い方 - 課題と対策 -

P.122 掲載の参考文献
1) Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC et al : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 : 2545-2559, 2008
 
2) ADVANCE Collaborative Group, Patel A et al : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 : 2560-2572, 2008
 
3) Hanafusa T, Imagawa A : Fulminant type 1 diabetes : a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 3 : 36-45; quiz 2p following 69, 2007
 
4) 田中昌一郎ほか : 緩徐進行1型糖尿病 (slowly progressive insulin-dependent diabetes mellitus : SPIDDM) の臨床的特徴-日本糖尿病学会1型糖尿病調査研究委員会緩徐進行1型糖尿病分科会報告 (第一報) -. 糖尿病 54 : 65-75, 2011
 
5) Vora J et al : Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus : a metaanalysis of endpoints in phase 3a trials. Diabetes Ther 5 : 435-446, 2014
PubMed
6) Pickup JC : Are insulin pumps underutilized in type 1 diabetes? Yes. Diabetes Care 29 : 1449-1452, 2006
PubMed
7) Maruyama T et al : Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 93 : 2115-2121, 2008
PubMed
8) Zhao Y et al : Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recentonset latent autoimmune diabetes in adults : one year prospective study. J Clin Endocrinol Metab 99 : E876-E880, 2014
 
P.131 掲載の参考文献
1) Huang ES et al : Rates of complications and mortality in older patients with diabetes mellitus : the diabetes and aging study. JAMA Intern Med 174 : 251-258, 2014
PubMed
2) 高齢者糖尿病の治療向上のための日本糖尿病学会と日本老年医学会の合同委員会 : 高齢者糖尿病の血糖コントロール目標について (http://www.jds.or.jp/modules/important/index.php?page=article&storyid=66)
 
3) Feil DG et al : Risk of hypoglycemia in older veterans with dementia and cognitive impairment : implications for practice and policy. J Am Geriatr Soc 59 : 2263-2272, 2011
 
4) Jaap AJ e t al : Perceived s ymptoms of hypoglycaemia in e lderly type 2 diabetic patients treated with insulin. Diabet Med 15 : 398-401, 1998
 
5) Bramlage P et al : Oral antidiabetic treatment in type-2 diabetes in the elderly : balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol 11 : 122, 2012
PubMed
6) Munshi MN et al : Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med 171 : 362-364, 2011
PubMed
7) Geller AI et al : National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med 174 : 678-686, 2014
PubMed
8) Pathak RD et al : Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems : 2005-2011. Diabetes Care 39 : 363-370, 2016
 
9) Hodge M et al : Hypoglycemia Incidence in Older Adults by Estimated GFR. Am J Kidney Dis, 2017 [Epub ahead of print]
 
10) Lee P et al : Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus : results from a pooled analysis. J Am Geriatr Soc 60 : 51-59, 2012
PubMed
11) Ji L et al : Comparative Effectiveness and Safety of Different Basal Insulins in a Real World Setting. Diabetes Obes Metab, 2017 [Epub ahead of print]
 
12) Sorli C et al : Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine : a meta-analysis of phase III a trials. Drugs Aging 30 : 1009-1018, 2013
 
13) Nagai Y et al : Efficacy and safety of thrice-weekly insulin degludec in elderly patients with type 2 diabetes assessed by continuous glucose monitoring. Endocr J 63 : 1099-1106, 2016
PubMed
14) Wolffenbuttel BH et al : Initiating insulin therapy in elderly patients with Type 2 diabetes : efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. Diabet Med 26 : 1147-1155, 2009
PubMed
15) Kumar S et al : Efficacy and safety of once-daily insulin degludec/insulin aspart compared with oncedaily insulin glargine in participants with Type 2 diabetes : a randomized, treat-to-target study. Diabet Med 34 : 180-188, 2017
PubMed
16) By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel : American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 63 : 2227-2246, 2015
 

5 合併症を有する高齢者糖尿病における糖尿病薬治療

P.139 掲載の参考文献
1) (社) 日本透析医学会 統計調査委員会 : 図説 我が国の慢性透析療法の現況, 2015
 
2) 糖尿病性腎症合同委員会 : 糖尿病性腎症病期分類の改訂について, 2013 (http://www.jsn.or.jp/academicinfo/ckd/dm_nephro.pdf)
 
3) Haneda M et al : A new Classification of Diabetic Nephropathy 2014 : a report from Joint Committee on Diabetic Nephropathy. J Diabetes Investig 6 : 242-246, 2015
PubMed
4) Haneda M et al : A new classification of Diabetic Nephropathy 2014 : a report from Joint Committee on Diabetic Nephropathy. Clin Exp Nephrol 19 : 1-5, 2015
 
5) 日本腎臓学会編 : CKD診療ガイド2012, 東京医学社, 2012
 
6) Simonsen O et al : The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 45 : 97-101, 1985
 
7) Abe M et al : Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis : metabolism and clinical practice. Curr Drug Metab 12 : 57-69, 2011
PubMed
8) セイブル(R) 添付文書 (http://database.japic.or.jp/pdf/newPINS/00051110.pdf)
 
9) Iglesias P et al : Diabetes mellitus and kidney disease in the elderly. Nefrologia 34 : 285-292, 2014
PubMed
10) Action to Control Cardiovascular Risk in Diabetes Study Group : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 : 2545-2559, 2008
 
11) ビグアナイド薬の適正使用に関する委員会 : メトホルミンの適正使用に関するRecommendation, 日本糖尿病学会, 2016
 
12) Hasslacher C ; Multinational Repaglinide Renal Study Group : Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 26 : 886-891, 2003
 
13) Abe M et al : Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocr J 57 : 579-586, 2010
PubMed
14) Strain WD et al : Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL) : a 24 week, randomised, double-blind, placebocontrolled study. Lancet 382 : 409-416, 2013
PubMed
15) Schweizer A, Dejager S : Experience with vildagliptin in patients > 75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther 4 : 257-267, 2013
PubMed
16) Barnett AH et al : Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments : a randomised, double-blind, placebo-controlled trial. Lancet 382 : 1413-1423, 2013
PubMed
17) Toh S et al : Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs : A Retrospective Cohort Study. Ann Intern Med 164 : 705-714, 2016
PubMed
18) Mikhail N : Place of s odium-glucose c o-transporter type 2 inhibitors for t reatment of type 2 diabetes. World J Diabetes 5 : 854-859, 2014
 
19) Araki H et al : Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment. J Diabetes Investig 5 : 435-441, 2014
 
20) Marso SP et al : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375 : 311-322, 2016
PubMed
P.144 掲載の参考文献
1) Kawamura T et al : Cognitive impairment in diabetic patients : Can diabetic control prevent cognitive decline? J Diabetes Investig 3 : 413-423, 2012
PubMed
2) 日本糖尿病学会編著 : 糖尿病治療ガイド2016-2017, 文光堂, 東京, 2016, pp97-98
 
3) Feil DG et al : Risk of hypoglycemia in older veterans with dementia and cognitive impairment : implications for practice and policy. J Am Geriatr Soc 59 : 2263-2272, 2011
 
4) Mattishent K, Loke YK : Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents : a systematic review and meta-analysis. Diabetes Obes Metab 18 : 135-141, 2016
PubMed
5) Tuligenga RH : Intensive glycaemic control and cognitive decline in patients with type 2 diabetes : a metaanalysis. Endocr Connect 4 : R16-R24, 2015
PubMed
6) Umegaki H : Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia. Drugs Aging 33 : 399-409, 2016
PubMed
7) Groeneveld ON et al : Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. J Diabetes Investig 7 : 5-16, 2016
PubMed
8) Stanley M et al : Changes in insulin and insulin signaling in Alzheimer's disease : cause or consequence? J Exp Med 213 : 1375-1385, 2016
PubMed
9) Ye F et al : Impact of Insulin Sensitizers on the Incidence of Dementia : A Meta-Analysis. Dement Geriatr Cogn Disord 41 : 251-260, 2016
PubMed
10) Heni M et al : Impaired insulin action in the human brain : causes and metabolic consequences. Nat Rev Endocrinol 11 : 701-711, 2015
PubMed

6 トピックス

P.151 掲載の参考文献
1) Barone BB et al : Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus : a systematic review and meta-analysis. JAMA 300 : 2754-2764, 2008
PubMed
2) Barone BB et al : Postoperative mortality in cancer patients with preexisting diabetes : systematic review and meta-analysis. Diabetes Care 33 : 931-939, 2010
PubMed
3) Ranc K et al : Mortality after cancer among patients with diabetes mellitus : effect of diabetes duration and treatment : (questionable) classification of diabetic patients based on combination of specific glucoselowering drugs. Reply to Holden SE, Bannister CA, Currie CJ [letter]. Diabetologia 57 : 2003-2004, 2014
 
4) Hotta N et al : Causes of death in Japanese diabetics : A questionnaire survey of 18,385 diabetics over a 10-year period. J Diabetes Investig 1 : 66-76, 2010
 
5) 糖尿病と癌に関する委員会 : 糖尿病と癌に関する委員会報告. 糖尿病 56 : 374-390, 2013
 
6) Noto H et al : Significantly increased risk of cancer in patients with diabetes mellitus : a systematic review and meta-analysis. Endocr Pract 17 : 616-628, 2011
PubMed
7) Noto H et al : Significantly increased risk of cancer in diabetes mellitus patients : A meta-analysis of epidemiologic evidence in Asians and non-Asians. J Diabetes Investig 3 : 24-33, 2012
PubMed
8) Larsson SC, Wolk A : Diabetes mellitus and incidence of kidney cancer : a meta-analysis of cohort studies. Diabetologia 54 : 1013-1018, 2011
PubMed
9) Sasazuki S et al : Diabetes mellitus and cancer risk : Pooled analysis of eight cohort studies in Japan. Cancer Sci 104 : 1499-1507, 2013
PubMed
10) Goto A et al : High hemoglobin A1c levels within the non-diabetic range are associated with the risk of all cancers. Int J Cancer 138 : 1741-1753, 2016
 
11) 糖尿病と癌に関する委員会 : 糖尿病と癌に関する委員会報告 第2報. 糖尿病 59 : 174-177, 2016
 
12) Colmers IN et al : Insulin use and cancer risk in patients with type 2 diabetes : a systematic review and meta-analysis of observational studies. Diabetes Metab 38 : 485-506, 2012
PubMed
13) ORIGIN Trial Investigators., Gerstein HC et al : Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 : 319-328, 2012
PubMed
14) Wu JW et al : Effect of Long-Acting Insulin Analogs on the Risk of Cancer : A Systematic Review of Observational Studies. Diabetes Care 39 : 486-494, 2016
 
15) Soranna D et al : Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes : a meta-analysis. Oncologist 17 : 813-822, 2012
PubMed
16) Chang CH et al : Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 97 : E1170-E1175, 2012
PubMed
17) Hosono K et al : Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 49 : 662-671, 2010
PubMed
18) Higurashi T et al : Metformin for chemoprevention of metachronous colorectal adenoma or polyps in postpolypectomy patients without diabetes : a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 17 : 475-483, 2016
PubMed
19) Noto H et al : Cancer risk in diabetic patients treated with metformin : a systematic review and metaanalysis. PLoS ONE 7 : e33411, 2012, doi : 10.1371/journal.pone.0033411.
 
20) Colmers IN et al : U se o f t hiazolidinediones and t he risk o f bladder c ancer among people with t ype 2 diabetes : a meta-analysis. CMAJ 184 : E675-E683, 2012
 
21) Azoulay L et al : Incretin based drugs and the risk of pancreatic cancer : international multicentre cohort study. BMJ 352 : i581, 2016
PubMed
22) 厚生労働省 : がん検診について. (http://www.mhlw.go.jp/bunya/kenkou/dl/gan_kenshin01.pdf), 2013
 
P.156 掲載の参考文献
1) Gispen WH, Biessels GJ : Cognition and synaptic plasticity in diabetic mellitus. Trends Neurosci 23 : 542-549, 2000
PubMed
2) Whitmer RA et al : Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301 : 1565-1572, 2009
PubMed
3) Ohara T e t al : Glucose tolerance s tatus and risk of dementia in the community : the Hisayama study. Neurology 77 : 1126-1134, 2011
 
4) Crane PK et al : Glucose levels and risk of dementia. N Engl J Med 369 : 540-548, 2013
PubMed
5) Craft S : Insulin resistance and Alzheimer's disease pathogenesis : potential mechanisms and implications for treatment. Curr Alzheimer Res 4 : 147-152, 2007
PubMed
6) Fernandez-Gamba A et al : Insulin-degrading enzyme : structure-function relationship and its possible roles in health and disease. Curr Pharm Des 15 : 3644-3655, 2009
PubMed
7) Frisardi V et al : Metabolic-cognitive syndrome : a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 9 : 399-417, 2010
PubMed
8) Steen E et al : Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7 : 63-80, 2005
PubMed
9) Bedse G et al : Aberrant insulin signaling in Alzheimer's disease : current knowledge. Front Neurosci 9 : 204, 2015
PubMed
10) De Felice FG, Ferreira ST : Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63 : 2262-2272, 2014
PubMed
11) Watson GS et al : Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone : a preliminary study. Am J Geriatr Psychiatry 13 : 950-958, 2005
PubMed
12) Craft S et al : Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment : a pilot clinical trial. Arch Neurol 69 : 29-38, 2012
PubMed
13) Bomfim TR et al : An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A β oligomers. J Clin Invest 122 : 1339-1353, 2012
 
P.162 掲載の参考文献
1) Vestergaard P : Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 18 : 427-444, 2007
PubMed
2) Yamamoto M et al : Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 24 : 702-709, 2009
 
3) Saito M et al : Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 17 : 1514-1523, 2006
PubMed
4) Starup-Linde J et al : Biochemical markers of bone turnover in diabetes patients-a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int 25 : 1697-1708, 2014
 
5) Kanazawa I et al : Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int 85 : 228-234, 2009
PubMed
6) Okazaki R et al : Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 82 : 2915-2920, 1997
PubMed
7) Kanazawa I et al : Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus. J Clin Endocrinol Metab 94 : 3031-3037, 2009
PubMed
8) Okazaki K et al : Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis. Calcif Tissue Int 91 : 286-296, 2012
 
9) Notsu M et al : Advanced glycation end product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells and human mesenchymal stem cells by increasing TGF- expression and secretion. Endocrinology 155 : 2402-2410, 2014
PubMed
10) Li J et al : Fracture is additionally attributed to hyperhomocysteinemia in men and premenopausal women with type 2 diabetes. J Diabetes Investig 5 : 236-241, 2014
PubMed
11) Thaler R e t al : H omocysteine s uppresses the e xpression of the c ollagen c ross-linker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation. J Biol Chem 286 : 5578-5588, 2011
 
12) Kanazawa I et al : Bazedoxifene Ameliorates Homocysteine-Induced Apoptosis and Accumulation of Advanced Glycation End Products by Reducing Oxidative Stress in MC3T3-E1 Cells. Calcif Tissue Int 100 : 286-297, 2017
PubMed
13) Burghardt AJ et al : High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95 : 5045-5055, 2010
PubMed
14) Dhaliwal R et al : Bone quality assessment in type 2 diabetes mellitus. Osteoporos Int 25 : 1969-1973, 2014
PubMed
15) Oei L et al : High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control : the Rotterdam Study. Diabetes Care 36 : 1619-1628, 2013
PubMed
16) Li CI et al : Glycated Hemoglobin Level and Risk of Hip Fracture in Older People with Type 2 Diabetes : A Competing Risk Analysis of Taiwan Diabetes Cohort Study. J Bone Miner Res 30 : 1338-1346, 2015
PubMed
17) Schwartz AV et al : Intensive glycemic control is not associated with fracture or falls in the ACCORD randomized trial. Diabetes Care 35 : 1525-1531, 2012
 
18) Yau RK et al : Diabetes and risk of hospitalized fall injury among older adults. Diabetes Care 36 : 3985-3991, 2013
PubMed
19) Loke YK et al : Long-term use of thiazolidinediones and fractures in type 2 diabetes : a meta-analysis. CMAJ 180 : 32-39, 2009
PubMed
20) 骨粗鬆症の予防と治療ガイドライン2015年版, 2015, pp.130-131
 
P.172 掲載の参考文献
1) Kitada M et al : Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes 5 : 342-356, 2014
PubMed
2) Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC et al : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 : 2545-2559, 2008
 
3) Goto A et al : Severe hypoglycaemia and cardiovascular disease : systematic review and meta-analysis with bias analysis. BMJ 347 : f4533, 2013
PubMed
4) Zinman B et al; EMPA-REG OUTCOME Investigators : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
5) Wu JH et al : Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes : a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4 : 411-419, 2016
PubMed
6) Kim M et al : GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19 : 567-575, 2013
 
7) Nystrom T et al : Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287 : E1209-E1215, 2004
PubMed
8) Ban K et al : Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117 : 2340-2350, 2008
PubMed
9) Marso SP et al; LEADER Steering Committee; LEADER Trial Investigators : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375 : 311-322, 2016
 
10) Wanner C et al; EMPA-REG OUTCOME Investigators : Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 375 : 323-334, 2016
PubMed
11) Marso SP et al; SUSTAIN-6 Investigators : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375 : 1834-1844, 2016
PubMed
P.177 掲載の参考文献
1) 鳥羽研二ほか : 薬剤起因性疾患. 日老医誌 36 : 181-185, 1999
 
2) Kojima T et al : High risk of adverse drug reactions in elderly patients taking six or more drugs : analysis of inpatient database. Geriatr Gerontol Int 12 : 761-762, 2012
PubMed
3) Kojima T et al : Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int 12 : 425-430, 2012
PubMed
4) American Geriatrics Society 2015 Beers Criteria Update Expert Panel : American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 63 : 2227-2246, 2015
 
5) O'Mahony D et al : STOPP/START criteria for potentially inappropriate prescribing in older people : version 2. Age Ageing 44 : 213-218, 2015
PubMed
6) 日本老年医学会, 日本医療研究開発機構研究費「高齢者の薬物治療の安全性に関する研究」研究班編 : 高齢者の安全な薬物療法ガイドライン2015, メジカルビュー社, 東京, 2015
 

書評

最近チェックした商品履歴

Loading...